Amgen vs Gilead Sciences
Explore a detailed comparison between Amgen Inc. and Gilead Sciences Inc., examining their distinct business models, financial performance, and relevant market context. This page provides an accessible overview for those seeking to understand key differences and similarities between these two prominent biotechnology companies. Educational content, not financial advice.
Explore a detailed comparison between Amgen Inc. and Gilead Sciences Inc., examining their distinct business models, financial performance, and relevant market context. This page provides an accessibl...
Why It's Moving
Amgen Faces Valuation Pressure Despite Market Outperformance as Analysts Warn of Downside Risk
- Amgen trades at a Forward P/E of 15.68, offering a discount to its industry average of 17.97, yet analysts project modest earnings growth of just 1.74% for the full year alongside 3.02% revenue expansion, raising questions about sustainable momentum.
- Expected upcoming earnings will show a 3.27% year-over-year EPS decline to $4.74 per share, signaling near-term profit pressure despite revenue projections of $8.51 billion, up 4.42% from the prior year quarter.
- The company's dividend remains solid with a $2.52 per share second-quarter payment announced for June 2026, though income support may not offset concerns about slowing earnings growth and execution risks ahead.
GILD Dividend Boost Signals Confidence Amid Mixed Analyst Signals on Downside Risks
- Board approves 3.8% dividend increase for Q1 2026, underlining strong financial health and commitment to shareholders.
- Recent $7.8B Arcellx acquisition bolsters oncology pipeline, building on HIV sales growth and Yescarta expansions.
- Jefferies Buy rating highlights EPS growth and upcoming Yetzugo launch, countering broader Wall Street downside forecasts.
Amgen Faces Valuation Pressure Despite Market Outperformance as Analysts Warn of Downside Risk
- Amgen trades at a Forward P/E of 15.68, offering a discount to its industry average of 17.97, yet analysts project modest earnings growth of just 1.74% for the full year alongside 3.02% revenue expansion, raising questions about sustainable momentum.
- Expected upcoming earnings will show a 3.27% year-over-year EPS decline to $4.74 per share, signaling near-term profit pressure despite revenue projections of $8.51 billion, up 4.42% from the prior year quarter.
- The company's dividend remains solid with a $2.52 per share second-quarter payment announced for June 2026, though income support may not offset concerns about slowing earnings growth and execution risks ahead.
GILD Dividend Boost Signals Confidence Amid Mixed Analyst Signals on Downside Risks
- Board approves 3.8% dividend increase for Q1 2026, underlining strong financial health and commitment to shareholders.
- Recent $7.8B Arcellx acquisition bolsters oncology pipeline, building on HIV sales growth and Yescarta expansions.
- Jefferies Buy rating highlights EPS growth and upcoming Yetzugo launch, countering broader Wall Street downside forecasts.
Investment Analysis
Amgen
AMGN
Pros
- Amgen maintains a robust oncology portfolio with blockbuster drugs like Lumakras driving consistent revenue growth.
- Rare disease franchise, including Tepezza, provides high-margin recurring revenues and shields against generic erosion.
- Strong balance sheet supports dividend growth and strategic acquisitions amid pipeline advancements.
Considerations
- Biosimilar competition erodes sales of key blockbusters such as Enbrel and Prolia.
- High R&D expenses pressure margins despite obesity drug progress in early stages.
- Regulatory delays in novel assets like MariTide expose pipeline execution risks.
Gilead Sciences
GILD
Pros
- Dominant HIV franchise with Yeztugo launch momentum bolsters market share alongside Descovy's 45% penetration.
- Attractive valuation at forward P/E of 14.19 trades at discount to industry peers.
- Expanding oncology pipeline nears key regulatory milestones for sustained growth.
Considerations
- Upcoming quarterly EPS projected to decline 1.58% year-over-year amid flat revenue.
- Recent insider sales signal potential short-term concerns over performance.
- Modest consensus price target implies limited near-term upside from current levels.
Related Market Insights
The Biotech Revolution: Why These Medical Pioneers Could Transform Your Portfolio
Explore the biotech revolution driven by CRISPR & regulatory support. Invest in leaders like Amgen, Gilead, Biogen. Discover high-growth medical pioneers.
Aimee Silverwood | Financial Analyst
July 25, 2025
The Cancer Treatment Revolution: Why Multiple Myeloma Breakthroughs Matter
Discover breakthrough multiple myeloma treatments. Invest in companies pioneering bispecific antibodies & CAR-T therapies driving the next cancer revolution. Explore the Neme.
Aimee Silverwood | Financial Analyst
July 25, 2025
AstraZeneca's Breakthrough Could Reshape Hypertension Treatment Forever
Explore the Hypertension Therapy Innovators Neme. AstraZeneca's baxdrostat breakthrough signals a new era in high blood pressure treatment. Invest in leading pharma giants.
Aimee Silverwood | Financial Analyst
July 25, 2025
Related Market Insights
The Biotech Revolution: Why These Medical Pioneers Could Transform Your Portfolio
Explore the biotech revolution driven by CRISPR & regulatory support. Invest in leaders like Amgen, Gilead, Biogen. Discover high-growth medical pioneers.
Aimee Silverwood | Financial Analyst
July 25, 2025
The Cancer Treatment Revolution: Why Multiple Myeloma Breakthroughs Matter
Discover breakthrough multiple myeloma treatments. Invest in companies pioneering bispecific antibodies & CAR-T therapies driving the next cancer revolution. Explore the Neme.
Aimee Silverwood | Financial Analyst
July 25, 2025
AstraZeneca's Breakthrough Could Reshape Hypertension Treatment Forever
Explore the Hypertension Therapy Innovators Neme. AstraZeneca's baxdrostat breakthrough signals a new era in high blood pressure treatment. Invest in leading pharma giants.
Aimee Silverwood | Financial Analyst
July 25, 2025
Amgen (AMGN) Next Earnings Date
Amgen's next earnings date is estimated between April 30, 2026, and May 4, 2026, as the company has not yet announced an official date, following its historical pattern after the February 3, 2026, release. This report will cover the first quarter of 2026 (Q1 2026) ending March 31, 2026. Investors should monitor for official confirmation in the coming weeks.
Gilead Sciences (GILD) Next Earnings Date
Gilead Sciences (GILD) is estimated to report its next earnings between April 23 and April 27, 2026, following the pattern of prior quarterly releases after its February 10, 2026 announcement for Q4 2025. This upcoming report will cover Q1 2026 results, with the exact date pending official confirmation. Investors should monitor for the formal announcement in the coming weeks.
Amgen (AMGN) Next Earnings Date
Amgen's next earnings date is estimated between April 30, 2026, and May 4, 2026, as the company has not yet announced an official date, following its historical pattern after the February 3, 2026, release. This report will cover the first quarter of 2026 (Q1 2026) ending March 31, 2026. Investors should monitor for official confirmation in the coming weeks.
Gilead Sciences (GILD) Next Earnings Date
Gilead Sciences (GILD) is estimated to report its next earnings between April 23 and April 27, 2026, following the pattern of prior quarterly releases after its February 10, 2026 announcement for Q4 2025. This upcoming report will cover Q1 2026 results, with the exact date pending official confirmation. Investors should monitor for the formal announcement in the coming weeks.
Which Baskets Do They Appear In?
Hypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketTop Biotech Stocks
Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.
Published: May 29, 2025
Explore BasketWhich Baskets Do They Appear In?
Hypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketTop Biotech Stocks
Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.
Published: May 29, 2025
Explore BasketBuy AMGN or GILD in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
